The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective

Area of Science:

• Hematology and Oncology
• Pathology
• Genetics

Background:

• Classical Burkitt's lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) represent distinct entities, yet a spectrum of disease exists.
• A challenging diagnostic gray zone, previously difficult to classify, is now recognized by the updated WHO classification as 'lymphoma, unclassifiable, with features intermediate between DLBCL and BL'.
• This intermediate category serves as a temporary classification for aggressive B-cell lymphomas with unclear lineage.

Purpose of the Study:

• To review the morphological, clinical, and biological heterogeneity of these intermediate lymphomas.
• To propose potential testable subgroups within this unclassifiable lymphoma category.
• To investigate the role of age and genetic aberrations in defining these subgroups.

Main Methods:

• Review of existing literature on aggressive B-cell lymphomas.
• Analysis of morphological and clinical features of intermediate lymphomas.
• Exploration of gene-expression data and genetic aberrations relevant to lymphoma classification.

Main Results:

• Intermediate lymphomas represent a heterogeneous group of aggressive B-cell lymphomas.
• Several subtypes within this category may be associated with unfavorable clinical outcomes.
• Age and specific genetic aberrations are proposed as potential criteria for subgrouping.

Conclusions:

• The 'intermediate' lymphoma classification highlights a critical diagnostic gap.
• Further research is needed to delineate distinct biological subtypes within this group.
• Identifying subgroups based on clinical and genetic factors may improve patient stratification and treatment strategies.